Rayek Nafiz

Rayek Nafiz

Auto-generated profile, based on publicly available information

Rayek Nafiz

University of Pennsylvania Health System, Division of Psychiatry, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KDKelly E Dyer
Kelly E Dyer
RRRebecca Russell
Rebecca Russell
RNRayek Nafiz
Rayek Nafiz
ABAngela Burdick-McPhee
Angela Burdick-McPhee
JOJean O’nEal
Jean O’nEal
JTJessie Torgersen
Jessie Torgersen
Background: People with substance use disorders (SUDs) are at higher risk for infectious diseases (IDs). Co-locating ID screening services within inpatient SUD treatment programs may decrease barriers to care; however, the impact of such screening has not been evaluated. Methods: We conducted an effectiveness study evaluating comprehensive ID screening within an 18-bed inpatient SUD program. During usual care (September 2021–June 2022), ID screening was completed at the discretion of the admitting psychiatrist. During the intervention (September 2022–June 2023), an ID-trained nurse met with patients to support completion of screening for HIV, viral hepatitis (hepatitis A [HAV], B [HBV], and C [HCV]), latent tuberculosis [LTBI], and sexually transmitted infections [STI]. Hepatitis vaccinations, HIV preexposure prophylaxis, and/or ID treatments were offered during admission. Results: Demographics were similar between the groups (n = 261, usual care; n = 207, intervention). Screening for ≥1 ID increased significantly during the intervention (60.2% vs 90.8%, P < .001), with the greatest increases in HAV (6.1% vs 90.3%, P < .001), HBV (8.8% vs 91.3%, P < .001), and LTBI (1.9% vs 67.8%, P < .001). HAV and HBV vaccinations increased from 0% to 58% and 71%, respectively. HCV viremia was identified in 15 usual care and 19 intervention patients, of whom 0% and 36.8% initiated direct-acting antiviral therapy within 2 weeks of testing. STIs were identified in 9.2% and 13.5% (P = .09) of the patients in the usual care and intervention groups. Conclusions: Comprehensive ID screening within inpatient SUD programs can increase uptake of testing and facilitate low-barrier delivery of preventive and therapeutic treatment.